Evidence map›Paper›PMID 42529191›Full record

ArticleThe Lancet regional health. Europe2026

Corrigendum to "Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis" The Lancet Regional Health - Europe, Volume 60, January 2026, 101524.

Célia Dupain, Nicolas Jacquin, Aurélien Latouche, Zoé Nevière, Pierre Gestraud, Abderaouf Hamza, Kenza Nedara, Vincent Cockenpot, Janick Selves, Yves Allory and 24 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

Célia DupainDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Nicolas JacquinDepartment of Medical Oncology, Institut Curie, Paris, France.
Aurélien LatoucheINSERM U1331, Institut Curie, Saint-Cloud, France and Paris-Saclay University, Paris, France.
Zoé NevièreDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Pierre GestraudINSERM U1331, Curie CoreTech Bioinformatics (CUBIC), Institut Curie Research Center, Mines ParisTech, Paris, France.
Abderaouf HamzaDepartment of Genetics, Institut Curie, Paris, France.
Kenza NedaraDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Vincent CockenpotDepartment of Pathology, Institut Curie, Paris, France.
Janick SelvesDepartment of Pathology, Institut Universitaire du Cancer Oncopole University Hospital of Toulouse, 31059, Toulouse, France.
Yves AlloryDepartment of Pathology, Institut Curie, Paris, France.
Laetitia ChanasData Office, Institut Curie, Paris, France.
Maud MilderData Office, Institut Curie, Paris, France.
Isabelle SoubeyranDepartment of Pathology, Institut Bergonié, Bordeaux, France.
Hélène BlonsInstitut du Cancer Paris Carpem, APHP Centre, Department of Biology, Pharmacogenomics and Molecular Oncology Unit, Hôpital Européen Georges Pompidou, Paris, France.
Anna PatrikidouDepartment of Cancer Medicine, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.
Axel de BernardiDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Julien Masliah-PlanchonDepartment of Genetics, Institut Curie, Paris, France.
Odette MarianiCenter of Biological Ressources, Institut Curie, Paris, France.
Etienne RouleauBiology and Pathology Department, Cancer Genetic Service, Gustave Roussy Cancer Center, U981, Université Paris-Saclay, Villejuif, France.
Fabienne EscandeCHRU Lille, Lille, France.
Sandrine BoyaultDepartment of Translationnal Research and Innovation, Centre de Recherche en Cancérologie de Lyon CRCL, INSERM U1052, CNRS UMR 5286, Centre Léon Bérard, UCBL1, Lyon, France.
Pierre SaintignyDepartment of Translationnal Research and Innovation, Centre de Recherche en Cancérologie de Lyon CRCL, INSERM U1052, CNRS UMR 5286, Centre Léon Bérard, UCBL1, Lyon, France.
Florence de FraipontCHU Grenoble, France.
Pierre BlancLaboratoire SeqOIA, France.
Jennifer WongDepartment of Genetics, Institut Curie, Paris, France.
Camille TlemsaniDepartment of Medical Oncology, Hôpital Cochin, APHP Centre, Université Paris Cité, Paris, France.
Isabelle GuillouDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Julie FlaviusDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Noemie FuentealbaDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Maud KamalDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Ivan BiècheDepartment of Genetics, Institut Curie, Paris, France.
Nicolas ServantINSERM U1331, Curie CoreTech Bioinformatics (CUBIC), Institut Curie Research Center, Mines ParisTech, Paris, France.
Christophe Le TourneauDepartment of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Sarah WatsonDepartment of Medical Oncology, Institut Curie, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.lanepe.2025.101524.].

Identifiers

PMID42529191
PMCPMC13416621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.